Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine + R-miniCHOP in Older Patients With Newly Diagnosed DLBCL
NCT04799275Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azacitidine in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), high grade B-cell lymphoma (HGBCL), sponsored by National Cancer Institute. Started May 2021; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04799275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799275.